Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers: A phase II randomized clinical trial  by Prymula, Roman et al.
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Background:  To provide  broader  protection  against  pneumococcal  disease,  new  vaccines  containing
conserved  Streptococcus  pneumoniae  proteins  are  being  developed.  This  study  assessed  the  safety,  reac-
togenicity  and  immunogenicity  of four  formulations  containing  pneumococcal  proteins  pneumolysin
toxoid  (dPly)  and  histidine  triad  protein  (PhtD)  in  toddlers.
Methods: In this  phase  II, multicenter,  observer-blind  study  (www.clinicaltrials.gov: NCT00985751)  con-
ducted  in the  Czech  Republic,  toddlers  (12–23  months)  were  randomized  (1:1:1:1:1)  to  receive  one  of
four  investigational  vaccine  formulations  (10  or 30 g each  of  dPly  and  PhtD,  alone  or in  combination
with  polysaccharide  conjugates  from  the  pneumococcal  non-typeable  Haemophilus  inﬂuenzae  protein-
D  conjugate  vaccine  [PHiD-CV]),  or the  licensed  PHiD-CV,  in  a 2-dose  primary  series  plus booster  at
study  months  0,  2 and  6.  Solicited  local  and  general  symptoms  were  recorded  within  seven  days  post-
vaccination,  unsolicited  symptoms  within  31  days  post-vaccination,  and serious  adverse  events  (SAEs)
during  the  entire  study  period.  Antibody  concentrations  against  the  vaccine  components  were  measured
pre-vaccination,  one  month  post-dose  2, pre-  and  one  month  post-booster.
Results: 257  toddlers  were  enrolled  and vaccinated.  Percentages  of  solicited  local  and  general  symptoms
following  the  different  investigational  formulations  were  generally  within  the  same  ranges  as  for  PHiD-
CV.  After  each  dose,  grade  3 fever  (>40.0 ◦C,  rectal measurement)  was  reported  for  maximum  one  toddler
in  each  group  with  no differences  between  investigational  formulations  and PHiD-CV  during  primary
vaccination.  23 SAEs  were  reported  for 17  toddlers,  with  distribution  balanced  between  all  groups  except
the  group  receiving  30  g dPly/PhtD  with  PHiD-CV-conjugates  (no  SAEs  reported).  None  of  the  SAEs  were
considered  to  be vaccine-related.For all  pneumococcal  protein-containing  formulations,  anti-PhtD  and  anti-Ply  antibody  geometric
mean  concentrations  increased  from  pre-vaccination  to post-dose  2 and from  pre-  to  post-booster  vac-
cination.
Conclusion:  All investigational  vaccine  formulations  were  well-tolerated  and immunogenic  when  admin-
istered  to  toddlers  as  a 2-dose  primary  vaccination  followed  by a  booster  dose.
Abbreviations: AE, adverse event; anti-PD, NTHi protein D antibody; ATP,
ccording-to-protocol; CI, conﬁdence interval; dPly, pneumolysin toxoid; ELISA,
nzyme-linked immunosorbent assay; GMC, geometric mean concentration; GMT,
eometric mean titer; LU, Luminex units; OPA, opsonophagocytic activity; PCV,
neumococcal conjugate vaccine; PHiD-CV, 10-valent pneumococcal non-typeable
aemophilus inﬂuenzae protein D conjugate vaccine; PhtD, histidine-triad protein D;
ly, pneumolysin; PS-conjugates, capsular polysaccharide conjugates; SAE, serious
dverse event; TVC, total vaccinated cohort.
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1. Introduction
Streptococcus pneumoniae, a leading cause of bacterial pneumo-
nia and invasive disease, is responsible for approximately 11% of
mortality in children under 5 years old worldwide [1,2]. Currently
available pneumococcal conjugate vaccines (PCVs) contain capsu-
lar polysaccharides of the most prevalent pneumococcal serotypes,
conjugated to a carrier protein (PS-conjugates). Widespread use of
these PCVs has signiﬁcantly decreased the incidence of pneumo-
coccal disease [3–5]. However, shifts in serotype epidemiology have
been noted [4–6]. Additionally, an increase in serotype 19A invasive
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neumococcal disease (IPD) has been observed in some countries,
artly due to multiple antibiotic resistance of this serotype [7–9]
nd no effective control after the introduction of a 7-valent PCV. A
ubstantial disease burden thus remained, necessitating the devel-
pment of new vaccines that could provide broader protection.
fter the recent introduction of the 19A-containing 13-valent PCV,
 decline in prevalence of serotype 19A was observed although
t remained one of the most common serotypes [10–12]. Another
pproach, different from multivalent conjugate vaccines, involves
he use of highly conserved pneumococcal proteins. Pneumolysin
oxoid (dPly) and histidine-triad protein D (PhtD) are potential can-
idates that have been shown to play a role in natural exposure [13]
nd induce disease protection in animal models [14–18].
We  evaluated the safety, reactogenicity and immunogenicity
f investigational vaccine formulations containing dPly and PhtD,
ither alone or in combination with the PS-conjugates of the 10-
alent pneumococcal non-typeable Haemophilus inﬂuenzae protein
 conjugate vaccine (PHiD-CV; SynﬂorixTM, GlaxoSmithKline Vac-
ines), when administered to healthy toddlers. In healthy adults,
hese formulations were well-tolerated and appeared immuno-
enic [19]. The primary objective of this study focused on the
ncidence of grade 3 fever (rectal temperature >40 ◦C), as febrile
eactions are common post-vaccination adverse reactions in chil-
ren that have consequences for parents and healthcare providers,
specially in terms of the resulting risk of febrile seizure.
.  Methodology
.1. Study design and objectives
This  phase II, randomized, observer-blind, controlled study
NCT00985751) was conducted in 10 centers in the Czech Republic
etween November 2009 and March 2011. The primary objective
as to assess the incidence of fever >40.0 ◦C (rectal temperature)
ithin seven days following at least one primary dose of the inves-
igational vaccine compared to PHiD-CV. Secondary objectives
ncluded safety, reactogenicity and immunogenicity assessment of
he investigational vaccines.
The study protocol was reviewed and approved by the Ethics
ommittee for Multicentre Clinical Trials of Faculty Hospital Hradec
ralove and local hospital ethics committees. The study was
onducted in accordance with Good Clinical Practice and the Dec-
aration of Helsinki. Written informed consent was obtained from
he parents or legally acceptable representative of each child before
nrolment.
This study has been registered at www.clinicaltrials.gov
NCT00985751). A protocol summary is available at http://www.
sk-clinicalstudyregister.com (study ID: 113171).
.2.  Participants and vaccines
Eligible  participants were healthy toddlers (12–23 months at
rst vaccination), without history of any hypersensitivity reac-
ion following previous vaccination, and who had not previously
een vaccinated against S. pneumoniae. Toddlers were excluded if
nother vaccine had been administered, or planned, from 30 days
efore and up to 30 days after administration of a study vaccine
ose.
Participants were randomized (1:1:1:1:1) using a central inter-
et randomization system (SBIR) to receive a 2-dose primary
accination series followed by booster vaccination. The study
omprised ﬁve visits at study months 0 (dose 1), 2 (dose 2), 3 (post-
rimary), 6 (pre-booster) and 7 (post-booster). All vaccines were
dministered intramuscularly with a 22–25 gauge needle (25 mm
ong) into the deltoid of the non-dominant arm or in the thigh if2 (2014) 3025–3034
the  deltoid size was  inadequate. Two  groups received a formula-
tion containing 10 or 30 g of each dPly and PhtD (dPly/PhtD-10
and dPly/PhtD-30). Two further groups received a formulation con-
taining the PS-conjugates of PHiD-CV (serotypes 1, 4, 5, 6B, 7F, 9V,
14, 18C, 19F and 23F) and 10 or 30 g of each dPly and PhtD (PHiD-
CV/dPly/PhtD-10 and PHiD-CV/dPly/PhtD-30). All investigational
vaccines were adjuvanted with aluminum phosphate. The ﬁfth
group received the licensed PHiD-CV [20]. All vaccines were man-
ufactured by GlaxoSmithKline Vaccines. No other vaccines were
co-administered.
2.3. Safety and reactogenicity assessment
Solicited and unsolicited adverse events (AEs) were recorded by
the participant’s parents in paper diary cards that were returned to
the investigator at the next study visit. Solicited local and general
symptoms were recorded within seven days post-vaccination and
unsolicited AEs within 31 days post-vaccination. Symptom inten-
sity was  graded on a scale of 1 (mild) to 3 (severe).
Serious adverse events (SAEs), deﬁned as any medical occur-
rence that resulted in death, disability or incapacity, was
life-threatening, or required hospitalization, were recorded over
the whole study period.
2.4.  Immunogenicity assessment
Blood  samples were collected pre-vaccination, one month post-
dose 2, and pre- and one month post-booster. Serum samples were
stored at −20 ◦C until analysis at GlaxoSmithKline’s laboratory, Rix-
ensart, Belgium and SGS laboratory, Wavre, Belgium.
Antibodies were quantiﬁed using an in-house multiplex assay
coated with protein D (PD), non-detoxiﬁed pneumolysin (Ply) and
PhtD, with a cut-off of 112 LU/mL for PD, 599 LU/mL for Ply and
391 LU/mL for PhtD. These cut-offs were based on the lower limit of
quantiﬁcation [21], the global variability of the assay at the highest
dilution and the lower limit of linearity.
Serotype-speciﬁc anti-capsular antibodies against the 10 PS-
conjugates and two  cross-reactive serotypes (6A, 19A) were
measured using a GlaxoSmithKline 22F-inhibition enzyme-linked
immunosorbent assay (ELISA), with a cut-off of 0.05 g/mL. An
antibody concentration of 0.2 g/mL measured by the 22F-ELISA is
equivalent to the antibody concentration of 0.35 g/mL measured
by the non-22F ELISA of the World Health Organization reference
laboratory [22].
Opsonophagocytic activity (OPA) for the above-mentioned anti-
bodies was measured by a pneumococcal killing assay with a cut-off
opsonic titer of 8, described previously [23].
2.5. Statistical analyses
Safety  and reactogenicity analyses were performed on the total
vaccinated cohort (TVC), comprising all toddlers with at least one
vaccine dose administration documented. To assess the impact of
each protein formulation on the incidence of grade 3 fever (primary
objective), the dPly/PhtD-10 and dPly/PhtD-30 groups were pooled,
as were the PHiD-CV/dPly/PhtD-10 and PHiD-CV/dPly/PhtD-30
groups, and group differences (pooled dPly/PhtD minus PHiD-CV
or pooled PHiD-CV/dPly/PhtD minus PHiD-CV) were calculated. The
groups were pooled based on the previously obtained safety results
in adults, in which the number of participants reporting fever was
similar for the respective 10 and 30 g formulations [19]. By pool-
ing the groups, the target sample size of 60 toddlers per group
(120 per pooled group) allowed for detection of a 10% increase
in absolute values of the prevalence of grade 3 fever with at least
90% power. The primary objective was reached if the asymptotic
standardized 95% conﬁdence interval (CI) of the deﬁned difference
cine 3
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ncluded 0, or if the upper limit of this 95% CI was below 10%.
ll other analyses were descriptive. Incidences of local and gen-
ral solicited symptoms and unsolicited AEs were calculated with
xact 95% CIs after each vaccine dose and for overall primary doses,
ccording to the type of symptom, intensity and relationship to
accination.
Descriptive immunogenicity analyses were performed on the
ccording-to-protocol (ATP) cohort for immunogenicity, compris-
ng vaccinated toddlers who met  all eligibility criteria, complied
ith the protocol-deﬁned procedures and intervals, and with
esults for at least one antibody assay available. ELISA geomet-
ic mean concentrations (GMCs) and OPA geometric mean titers
GMTs) with 95% CIs and seropositivity rates with exact 95% CIs
ere determined for each vaccine serotype or antigen. Analyses
ere performed with Statistical Analysis System (SAS® Institute
nc., Cary, NC).
.  Results
.1. Study participants and demographics
Of the 257 vaccinated toddlers, 256 completed the study and 220
ere included in the ATP cohort for immunogenicity (Fig. 1). One
oddler in the PHiD-CV group was withdrawn due to a non-serious
E (eczema), not considered to be causally related to vaccination
y the investigators.
Demographic characteristics were similar between groups. The
ean age in the TVC was 16.8 ± 3.9 months at dose 1 (range:
2–24 months) and 23.2 ± 4.0 months at booster vaccination
ig. 1. Participant ﬂow diagram TVC, total vaccinated cohort; ATP, according-to-protoc
peciﬁed characteristics.2 (2014) 3025–3034 3027
(range: 17–30 months). Most toddlers (98.8%) were of white-
Caucasian/European heritage and 50.6% were male.
3.2.  Safety and reactogenicity
Post-dose  1, grade 3 fever was  reported for one toddler in
the pooled dPly/PhtD group and one toddler in the pooled PHiD-
CV/dPly/PhtD group; no grade 3 fever was reported for toddlers
in the PHiD-CV group (difference in rates, for each comparison:
0.97% [−6.10 to 5.32]). No grade 3 fever was  reported post-dose 2 or
post-booster. No statistically signiﬁcant differences were detected
in the incidence of grade 3 fever during primary vaccination with
investigational formulations (protein alone or combined with PS-
conjugates) compared to PHiD-CV; thus the primary objective was
reached.
Incidences of solicited local and general symptoms after vacci-
nation with the investigational formulations were generally within
the same ranges as for PHiD-CV, except swelling which was
reported less frequently post-dose 1 in the dPly/PhtD-30 group
(Figs. 2 and 3). Pain and redness were the most common solicited
local symptoms after both primary doses (Fig. 2). Incidences of
solicited local grade 3 symptoms post-dose 1 and 2 were low (≤9.6%
of investigational vaccine recipients and ≤7.8% of PHiD-CV recipi-
ents) (Fig. 2).Post-booster, pain was  the most common solicited local symp-
tom for most groups (Fig. 2). Speciﬁc grade 3 solicited local
symptoms were reported for 0.0–9.6% of investigational vaccine
recipients and for 0.0–6.0% of PHiD-CV recipients (Fig. 2).
ol; N, number of toddlers in the speciﬁed group; n, number of toddlers with the
3028 R. Prymula et al. / Vaccine 32 (2014) 3025–3034
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hose  with a diameter of >30 mm,  and for pain: crying when limb was  moved. Error
Irritability was the most common solicited general symptom
ollowing primary and booster vaccination (Fig. 3). One or more
olicited general symptoms were reported for up to 59.6% of par-
icipants post-dose 1, 47.1% post-dose 2 and 50.0% post-booster in
he investigational groups, and for up to 51.0% post-dose 1, 54.0%
ost-dose 2 and 38.0% post-booster in the PHiD-CV group (Fig. 3).
Incidences of grade 3 solicited general symptoms ranged from
.0% to 3.9% post-dose 1 and from 0.0% to 2.0% post-dose 2 in the
nvestigational groups; none were reported for PHiD-CV, except
rritability post-dose 2 (2.0%). Post-booster, grade 3 solicited gen-
ral symptoms were reported by 0.0–3.9% of investigational vaccine
ecipients and by 0.0–2.0% of PHiD-CV recipients (Fig. 3).
Five  large swelling reactions were reported: one occurring post-
ose 1 and three post-booster in the PHiD-CV/dPly/PhtD-10 group,
nd one post-dose 2 in the PHiD-CV group. All large swelling reac-
ions were local reactions around the injection site with a diameter
f 53–100 mm and onset on day 0 or 1 after vaccination. All resolved
ompletely within maximum two days.
Unsolicited AEs considered vaccine-related were reported for
ne toddler (injection site ﬁbrosis) following dPly/PhtD-10 primary
accination, for two toddlers (vomiting and injection site ﬁbrosis)
fter dPly/PhtD-10 booster, for one toddler (rhinitis) after PHiD-
V/dPly/PhtD-10 booster and for one toddler (rhinitis, insomnia
nd cough) after PHiD-CV/dPly/PhtD-30 booster.
Grade 3 unsolicited AEs were reported for 11 toddlers after pri-
ary vaccination (Table S1) and for one toddler after dPly/PhtD-30
ooster vaccination (cystitis).
Overall,  23 SAEs were reported in 17 toddlers (ﬁve, dPly/PhtD-
0; three, dPly/PhtD-30; ﬁve, PHiD-CV/dPly/PhtD-10; four, PHiD-
V). None of the SAEs were fatal or considered by the investigators
o be vaccine-related; all resolved without sequelae except one
type 1 diabetes mellitus), which was improving at the time of study
nd. period (total vaccinated cohort) Grade 3 symptoms for redness and swelling were
indicate 95% conﬁdence intervals.
3.3. Immunogenicity
3.3.1. Immune response to pneumococcal proteins PhtD and Ply
Pre-dose  1, 61.0–75.6% of toddlers in each group were seropos-
itive for PhtD (antibody concentration ≥391 LU/mL). In the
investigational vaccine groups, these percentages increased to at
least 97.7% one month post-dose 2 and pre-booster, reaching 100%
post-booster. In the PHiD-CV group, 85.0–85.4% of toddlers were
seropositive for anti-PhtD antibodies at these post-vaccination
timepoints (Table 1).
A  high baseline seropositivity rate for anti-Ply antibodies
(antibody concentrations ≥599 LU/mL) was  seen in all groups
(75.0–88.6%). Seropositivity rates increased in all investigational
groups to at least 97.7% one month post-dose 2, and to 100% both
pre- and post-booster vaccination. In the PHiD-CV group, seropos-
itivity rates ranged from 87.5% to 90.2% at one month post-dose 2,
pre-booster and one month post-booster (Table 2).
In  the groups receiving pneumococcal protein-containing for-
mulations, antibody GMCs increased 8.5–16.3-fold for anti-PhtD
antibodies and 8.2–54.2-fold for anti-Ply antibodies from pre-
vaccination to post-dose 2. One month post-booster, antibody
GMCs for both PhtD and Ply were 2.2–3.2-fold higher than pre-
booster and 1.4–2.2-fold higher than post-dose 2 (Tables 1 and 2).
3.3.2.  Immune response to pneumococcal serotype-speciﬁc
PS-conjugates and to protein D
Before vaccination, for each vaccine serotype, a maximum
of 15.8% of toddlers in the groups receiving formulations
with PS-conjugates had serotype-speciﬁc antibody concentrations
≥0.2 g/mL. One month post-dose 2, for each vaccine serotype,
at least 97.5% of toddlers receiving a PHiD-CV/dPly/PhtD for-
mulation had antibody concentrations ≥0.2 g/mL, except for
serotypes 6B (≥78.3%) and 23F (≥89.7%); for PHiD-CV recipients,
R. Prymula et al. / Vaccine 32 (2014) 3025–3034 3029
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ars  indicate 95% conﬁdence intervals.
t least 97.6% had antibody concentrations ≥0.2 g/mL except for
erotypes 6B (85.4%) and 23F (92.7%). In the groups that did not
eceive PS-conjugates, 0.0–17.1% of toddlers had antibody con-
entrations ≥0.2 g/mL; similar ranges were observed pre- and
ost-vaccination (Table S2).
Before booster vaccination, for each vaccine serotype, at least
2.5% of PHiD-CV/dPly/PhtD recipients and at least 95.0% of PHiD-
V recipients had antibody concentrations ≥0.2 g/mL, except for
erotypes 6B (≥75.0% and ≥77.5%, respectively) and 23F (≥87.8%
nd ≥92.5%). Post-booster, for each vaccine serotype, these per-
entages were at least 97.9% in the PHiD-CV/dPly/PhtD groups
xcept 6B (≥89.4%), and at least 97.5% in the PHiD-CV group
xcept 6B (95.0%). The percentage of toddlers with pneumococcal
erotype-speciﬁc anti-capsular antibodies above 0.2 g/mL were
hus within similar ranges for the PHiD-CV/dPly/PhtD groups and
he PHiD-CV group, both after 2-dose priming and post-booster
Table S2).
Post-primary vaccination, at least 80.0% of toddlers in the PHiD-
V/dPly/PhtD groups had OPA titers ≥8 for each vaccine serotype
xcept for 6B (≥74.1%), compared to 87.1% of toddlers in the
HiD-CV group. For each vaccine serotype, at least 42.9% of PHiD-
V/dPly/PhtD recipients and at least 52.9% of PHiD-CV recipients
ad OPA titers ≥8 before booster vaccination. Post-booster, these
ercentages increased to at least 89.2% in the PHiD-CV/dPly/PhtDon period (total vaccinated cohort) Grade 3 symptoms for irritability were deﬁned
perature >40.0 ◦C, and for all other events: those preventing normal activity. Error
groups (except 6B: ≥84.8%) and at least 94.6% in the PHiD-CV group
(Table S3).
In  all groups receiving formulations containing PS-conjugates,
for each vaccine serotype, increases in antibody GMCs and OPA
GMTs were observed from pre- to post-primary vaccination and
from pre- to post-booster. Booster vaccination elicited similar or
higher antibody GMC  and OPA GMT  values compared to the post-
dose 2 values (Tables 3A and 3B).
Before vaccination, 19.5–31.8% of PS-conjugate recipients were
seropositive for anti-PD antibodies. Post-dose 2, 97.4–100% of
toddlers in these groups were seropositive. At the pre-booster time-
point, 87.5–91.3% of PHiD-CV/dPly/PhtD recipients and 97.5% of
PHiD-CV recipients were seropositive. Post-booster, seropositivity
rates increased to 97.6–100% of toddlers. Anti-PD antibody GMCs
increased from pre- to post-primary vaccination and from pre- to
post-booster for all PD-containing formulations (Table 3A).
4.  Discussion
Four investigational vaccine formulations containing dPly and
PhtD, with or without PS-conjugates, showed a similar safety
and reactogenicity proﬁle to that of PHiD-CV in toddlers. No
statistically signiﬁcant difference was  detected in the incidence of
grade 3 fever following at least one primary vaccine dose between
3030
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Table 1
Percentage of toddlers with anti-PhtD antibody concentrations ≥391 LU/mL, and anti-PhtD antibody GMCs prior to primary and booster vaccination and 1 month after primary and booster vaccination (according-to-protocol
cohort for immunogenicity).
dPly/PhtD-10 dPly/PhtD-30 PHiD-CV/dPly/PhtD-10 PHiD-CV/dPly/PhtD-30 PHiD-CV
N  % ≥391 LU/mL
(95%  CI)
GMC
(95%  CI)
N  % ≥391 LU/mL
(95%  CI)
GMC
(95%  CI)
N  % ≥391 LU/mL
(95%  CI)
GMC
(95%  CI)
N  % ≥  391  LU/mL
(95%  CI)
GMC
(95%  CI)
N  %  ≥391 LU/mL
(95%  CI)
GMC
(95%  CI)
Pre-vac. 44 75.0
(59.7–86.8)
1923
(1131–3270)
44  75.0
(59.7–86.8)
2695
(1563–4646)
44  72.7
(57.2–85.0)
2743
(1536–4897)
41  61.0
(44.5–75.8)
1362
(765–2426)
41  75.6
(59.7–87.6)
2559
(1500–4364)
Post-dose  2 45 97.8
(88.2–99.9)
30403
(20724–44603)
43  97.7
(87.7–99.9)
35044
(24164–50822)
45  100
(92.1–100)
23438
(16618–33057)
39  100
(91.0–100)
22141
(15065–32540)
41  85.4
(70.8–94.4)
3796
(2268–6352)
Pre-booster  44 100
(92.0–100)
24351
(17056–34765)
45  100
(92.1–100)
23919
(17725–32278)
46  97.8
(88.5–99.9)
14376
(9338–22130)
40  100
(91.2–100)
12721
(8498–19043)
40  85.0
(70.2–94.3)
4815
(2881–8046)
Post-booster  44 100
(92.0–100)
65584
(50985–84363)
43  100
(91.8–100)
77312
(58589–102018)
47  100
(92.5–100)
32609
(23616–45028)
41  100
(91.4–100)
36098
(26621–48949)
41  85.4
(70.8–94.4)
5072
(3024–8509)
N, Number of toddlers with available results; GMC, geometric mean concentration; 95% CI, 95% conﬁdence interval.
Table 2
Percentage of toddlers with anti-Ply antibody concentrations ≥599 LU/mL, and anti-Ply antibody GMCs prior to and 1 month after primary and booster vaccination (according-to-protocol cohort for immunogenicity).
dPly/PhtD-10  dPly/PhtD-30  PHiD-CV/dPly/PhtD-10  PHiD-CV/dPly/PhtD-30  PHiD-CV
N  %  ≥599  LU/mL
(95%  CI)
GMC
(95%  CI)
N  %  ≥599  LU/mL
(95%  CI)
GMC
(95%  CI)
N  %  ≥599  LU/mL
(95%  CI)
GMC
(95%  CI)
N  %  ≥599  LU/mL
(95%  CI)
GMC
(95%  CI)
N  %  ≥599  LU/mL
(95%  CI)
GMC
(95%  CI)
Pre-vac.  44  84.1
(69.9–93.4)
3104
(1938–4971)
44 75.0
(59.7–86.8)
2741
(1672–4493)
44 88.6
(75.4–96.2)
3976
(2610–6057)
41 78.0
(62.4–89.4)
2200
(1369–3536)
41 87.8
(73.8–95.9)
3180
(2006–5042)
Post-dose 2  45  97.8
(88.2–99.9)
135704
(95377–193081)
43 97.7
(87.7–99.9)
148448
(101600–216897)
45 100
(92.1–100)
32436
(25524–41220)
39 100
(91.0–100)
57150
(44909–72728)
41 90.2
(76.9–97.3)
3760
(2377–5948)
Pre-booster 44  100
(92.0–100)
100811
(74006–137327)
45 100
(92.1–100)
96553
(73754–126399)
46 100
(92.3–100)
19574
(14948–25630)
40 100
(91.2–100)
29592
(22065–39689)
40 87.5
(73.2–95.8)
4654
(2879–7523)
Post-booster 44  100
(92.0–100)
224726
(178188–283420)
43 100
(91.8–100)
305912
(248088–377214)
47 100
(92.5–100)
44123
(34300–56760)
41 100
(91.4–100)
85805
(67741–108687)
41 90.2
(76.9–97.3)
4553
(2878–7204)
N, Number of toddlers with available results; GMC, geometric mean concentration; 95% CI, 95% conﬁdence interval.
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he investigational vaccines and PHiD-CV, conﬁrming the primary
bjective. Reactogenicity of the investigational vaccines did not
ppear to be dose-dependent.
All  dPly/PhtD-containing vaccines induced robust anti-protein
mmune responses following primary and booster vaccination. The
rotein-only formulations tended to be more immunogenic than
he formulations combining the proteins with PS-conjugates, both
n primary and booster vaccination. As no immunological corre-
ates of protection have yet been established for the pneumococcal
roteins, the clinical relevance of this ﬁnding is not known. Addi-
ion of dPly and PhtD to the conjugate vaccine formulations did not
ppear to have a negative effect on the immune response to the
S-conjugates.
able 3A
ntibody GMCs (22F-inhibition ELISA) against the vaccine pneumococcal serotypes and 
accination (according-to-protocol cohort for immunogenicity).
PHiD-CV/dPly/PhtD-10 PHiD
N GMC  (95% CI) N 
Vaccine serotypes
1  Pre-vac. 44 0.04 (0.03–0.06) 41 
Post-dose  2 46 2.50 (2.01–3.11) 40 
Pre-booster 45 0.87 (0.68–1.12) 40 
Post-booster 47 2.69 (2.13–3.39) 41 
4  Pre-vac. 44 0.03 (0.03–0.04) 40 
Post-dose  2 46 6.42 (5.23–7.87) 40 
Pre-booster 46 2.30 (1.82–2.91) 41 
Post-booster 47 5.26 (4.14–6.69) 41 
5  Pre-vac. 42 0.05 (0.04–0.06) 39 
Post-dose  2 44 2.42 (1.85–3.17) 39 
Pre-booster 45 1.08 (0.83–1.41) 41 
Post-booster 47 3.57 (2.79–4.57) 41 
6B  Pre-vac. 40 0.03 (0.02–0.03) 39 
Post-dose  2 46 0.55 (0.37–0.81) 40 
Pre-booster 44 0.39 (0.28–0.54) 40 
Post-booster 47 1.08 (0.74–1.57) 41 
7F  Pre-vac. 44 0.04 (0.03–0.05) 41 
Post-dose  2 46 5.03 (4.16–6.09) 40 
Pre-booster 46 2.60 (2.14–3.15) 41 
Post-booster 47 5.90 (4.83–7.20) 41 
9V  Pre-vac. 43 0.04 (0.03–0.05) 39 
Post-dose  2 46 2.81 (2.24–3.51) 40 
Pre-booster 45 1.44 (1.15–1.81) 41 
Post-booster 47 3.13 (2.48–3.93) 41 
14  Pre-vac. 44 0.07 (0.05–0.11) 41 
Post-dose  2 46  5.18 (3.91–6.86) 40 
Pre-booster 46 2.86 (2.25–3.65) 40 
Post-booster 47 7.74 (6.03–9.94) 41 
18C  Pre-vac. 43 0.03 (0.03–0.04) 39 
Post-dose  2 45 13.92 (10.75–18.03) 40 
Pre-booster 45 4.94 (3.83–6.38) 41 
Post-booster 47 16.12 (12.20–21.32) 41 
19F  Pre-vac. 43 0.04 (0.03–0.05) 38 
Post-dose  2 45 8.60 (6.37–11.63) 39 
Pre-booster 46 4.15 (2.94–5.85) 41 
Post-booster 47 10.46 (7.35–14.88) 41 
23F  Pre-vac. 44 0.03 (0.03–0.03) 38 
Post-dose  2 45 1.19 (0.82–1.74) 39 
Pre-booster 45 0.71 (0.50–0.99) 41 
Post-booster 47 1.92 (1.42–2.60) 41 
Cross-reactive  serotypes
6A  Pre-vac. 45 0.03 (0.03–0.04) 39 
Post-dose  2 43 0.32 (0.20–0.51) 40 
Pre-booster 44 0.24 (0.17–0.34) 41 
Post-booster 47 0.53 (0.35–0.79) 41 
19A  Pre-vac. 42 0.04 (0.03–0.06) 39 
Post-dose  2 43 1.08 (0.71–1.62) 39 
Pre-booster 44 0.85 (0.61–1.17) 41 
Post-booster 47 2.76 (1.92–3.96) 41 
Protein  D (LU/mL)
Pre-vac.  44 98.8 (75.0–130.0) 41 
Post-dose  2 45 1105.4 (833.7–1465.7) 39 
Pre-booster 46 734.6 (523.9–1030.1) 40 
Post-booster  47 1882.6 (1407.4–2518.1) 41 
, Number of toddlers with available results; GMC, geometric mean concentration; 95% C2 (2014) 3025–3034 3031
No clear trend for dose-dependency of the immune response
was observed. Another study evaluating different PhtD-containing
formulations showed a stronger immune response to the 25 g
dose than to the 6 g dose, but no difference between the 25
and 100 g doses [24]. Dose-related increases in immunogenicity
were also observed for other vaccine formulations containing 10 or
20 g PhtD and pneumococcal choline-binding protein A (PcpA),
with no further increase for the 50 g dose [25], and for 10 and
25 g doses of a dPly-containing vaccine, with no further increasecross-reactive serotypes 6A and 19A prior and 1 month after primary and booster
-CV/dPly/PhtD-30 PHiD-CV
GMC (95% CI) N GMC  (95% CI)
0.05 (0.04–0.07) 41 0.03 (0.03–0.04)
2.08 (1.56–2.77) 41 2.13 (1.62–2.79)
0.75 (0.57–0.99) 40 0.73 (0.55–0.97)
2.47 (2.03–3.00) 41 2.40 (1.85–3.12)
0.04 (0.03–0.06) 41 0.03 (0.02–0.03)
6.60 (5.12–8.52) 41 5.67 (4.56–7.06)
2.36 (1.79–3.11) 40 2.11 (1.68–2.64)
5.61 (4.46–7.07) 41 5.18 (4.05–6.63)
0.05 (0.04–0.07) 39 0.05 (0.04–0.06)
2.41 (1.85–3.13) 41 2.36 (1.88–2.97)
1.05 (0.81–1.36) 40 1.18 (0.94–1.48)
3.45 (2.70–4.41) 41 3.84 (2.98–4.95)
0.04 (0.03–0.05) 41 0.03 (0.02–0.04)
0.48 (0.32–0.72) 41 0.55 (0.39–0.78)
0.42 (0.30–0.59) 40 0.46 (0.34–0.62)
1.14 (0.83–1.57) 40 1.08 (0.78–1.52)
0.04 (0.03–0.06) 41 0.03 (0.03–0.04)
4.73 (3.89–5.74) 41 3.72 (3.17–4.36)
2.36 (1.94–2.86) 40 2.14 (1.82–2.51)
5.25 (4.36–6.32) 41 4.65 (3.77–5.72)
0.04 (0.03–0.06) 41 0.03 (0.02–0.03)
2.49 (1.95–3.19) 41 1.55 (1.21–2.00)
1.26 (0.94–1.67) 40 0.95 (0.73–1.24)
3.21 (2.45–4.19) 40 2.18 (1.71–2.79)
0.06 (0.04–0.08) 41 0.06 (0.04–0.09)
3.78 (2.92–4.91) 41 4.63 (3.71–5.77)
2.30 (1.81–2.91) 40 2.71 (2.17–3.38)
6.62 (5.22–8.40) 41 5.98 (4.68–7.63)
0.05 (0.03–0.07) 41 0.03 (0.02–0.04)
16.92 (13.61–21.03) 41 12.56 (9.80–16.10)
5.51 (4.30–7.05) 40 4.79 (3.69–6.21)
21.98 (16.67–28.99) 40 14.62 (10.90–19.60)
0.06 (0.04–0.09) 39 0.04 (0.03–0.06)
10.08 (7.21–14.09 41 8.87 (6.20–12.70)
4.72 (3.54–6.30) 40 4.33 (3.06–6.12)
14.38 (10.53–19.63) 41 11.32 (7.94–16.13)
0.03 (0.03–0.04) 40 0.03 (0.02–0.03)
0.91 (0.62–1.33) 41 0.73 (0.54–0.98)
0.62 (0.45–0.85) 40 0.51 (0.39–0.67)
2.04 (1.56–2.65) 40 1.47 (1.04–2.06)
0.04 (0.03–0.07) 41 0.03 (0.03–0.04)
0.27 (0.16–0.45) 41 0.31 (0.20–0.48)
0.24 (0.15–0.38) 40 0.27 (0.18–0.40)
0.56 (0.36–0.87) 40 0.58 (0.37–0.90)
0.05 (0.03–0.07) 39 0.03 (0.03–0.04)
0.97 (0.63–1.48) 41 0.93 (0.61–1.43)
0.68 (0.47–0.98) 40 0.62 (0.42–0.93)
2.98 (2.08–4.26) 41 2.06 (1.30–3.25)
85.6 (68.7–106.6) 41 78.9 (62.2–100.3)
600.2 (426.5–844.7) 41 860.0 (659.2–1121.9)
463.0 (330.2–649.3) 40 691.8 (527.6–907.1)
1474.6 (1103.7–1970.3) 41 1963.8 (1560.1–2472.0)
I, 95% conﬁdence interval.
for the 50 g dose [26]. However, these studies involved adults
whereas our study investigated toddlers, which could partially
explain the difference in dose-dependency; toddlers have a less
mature immune system which could result in a different immune
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Table  3B
Functional antibody (OPA) GMTs against the vaccine pneumococcal serotypes and cross-reactive serotypes 6A and 19A prior to and 1 month after primary and booster
vaccination (according-to-protocol cohort for immunogenicity).
PHiD-CV/dPly/PhtD-10 PHiD-CV/dPly/PhtD-30 PHiD-CV
N OPA GMT  (95% CI) N OPA GMT  (95% CI) N OPA GMT  (95% CI)
Vaccine serotypes
1  Pre-vac. 32 4.3 (3.7–5.1) 31 5.0 (3.2–7.7) 35 4.7 (3.7–6.2)
Post-dose  2 35 71.8 (40.9–126.1) 30 48.2 (26.5–87.6) 30 90.0 (52.9–153.0)
Pre-booster  33 23.0 (13.1–40.3) 35 12.4 (7.6–20.3) 34 19.3 (11.1–33.6)
Post-booster  37 169.5 (96.1–298.8) 36 200.0 (138.2–289.4) 37 206.9 (123.1–347.5)
4  Pre-vac. 31 4.0 (4.0–4.0) 26 9.6 (4.1–22.9) 35 8.4 (4.4–15.9)
Post-dose  2 32 1260.2 (856.1–1855.2) 29 1197.9 (784.1–1830.2) 29 1220.4 (913.8–1629.9)
Pre-booster  29 247.9 (117.4–523.2) 33 259.9 (120.6–560.0) 30 478.9 (309.3–741.3)
Post-booster  35 1206.2 (888.9–1636.8) 32 1385.0 (974.5–1968.4) 34 1476.0 (1076.0–2024.6)
5  Pre-vac. 34 4.0 (4.0–4.0) 31 4.0 (4.0–4.0) 35 4.0 (4.0–4.0)
Post-dose  2 33 43.8 (27.1–70.8) 30 37.3 (21.7–64.0) 31 42.0 (26.6–66.4)
Pre-booster  34 12.8 (8.2–19.9) 33 14.8 (9.6–23.0) 34 17.0 (10.9–26.4)
Post-booster  37 99.3 (62.1–158.8) 34 110.4 (73.1–166.8) 36 160.7 (113.0–228.7)
6B  Pre-vac. 23 9.2 (3.5–24.0) 27 6.1 (3.3–11.3) 32 11.7 (5.1–26.6)
Post-dose  2 27 361.9 (120.0–1091.7) 25 527.5 (202.6–1372.9) 28 915.3 (543.4–1541.8)
Pre-booster  30 213.8 (79.0–578.1) 30 513.1 (243.9–1079.6) 30 371.9 (172.5–801.8)
Post-booster  33 804.6 (343.5–1884.9) 34 982.7 (527.6–1830.4) 35 1523.1 (875.8–2649.0)
7F  Pre-vac. 24 627.8 (274.3–1437.1) 20 460.5 (159.8–1327.1) 26 916.7 (468.0–1795.7)
Post-dose  2 33 5703.7 (4143.6–7851.2) 29 4936.6 (3320.7–7338.7) 30 6154.4 (4244.4–8923.7)
Pre-booster  32 2450.1 (1637.4–3666.2) 34 2713.5 (1836.1–4010.1) 33 3844.5 (2725.7–5422.4)
Post-booster  35 4109.3 (3086.9–5470.3) 33 5730.4 (4262.0–7704.7) 36 7404.7 (5271.1–10401.8)
9V  Pre-vac. 24 17.4 (6.2–48.7) 23 18.6 (6.6–52.3) 25 38.8 (12.9–116.1)
Post-dose  2 34 4455.0 (2803.3–7079.9) 29 3542.8 (2271.5–5525.5) 30 3947.2 (2612.7–5963.5)
Pre-booster  32 2126.1 (1140.2–3964.4) 33 2622.4 (1786.7–3849.0) 32 3450.0 (2357.5–5048.7)
Post-booster  27 4643.1 (3418.3–6306.9) 34 5802.4 (4453.0–7560.8) 36 6016.6 (4617.2–7840.0)
14  Pre-vac. 23 9.4 (4.5–19.5) 25 10.1 (4.6–22.0) 28 17.9 (7.3–44.2)
Post-dose  2 33 3324.8 (2324.8–4754.8) 29 2580.7 (1788.4–3724.0) 31 2487.6 (1703.4–3632.7)
Pre-booster  32 1390.5 (615.7–3140.4) 34 1725.8 (972.1–3064.0) 33 1776.6 (1009.5–3126.5)
Post-booster  34 2911.6 (1841.3–4604.0) 36 3729.8 (2693.2–5165.4) 37 3094.0 (2353.3–4068.0)
18C  Pre-vac. 27 4.0 (4.0–4.0) 26  5.8 (3.4–10.1) 32 5.1 (3.6–7.1)
Post-dose  2 33 1398.3 (810.6–2412.0) 28 2538.4 (1787.3–3605.0) 27 1905.4 (1271.4–2855.6)
Pre-booster  31 420.1 (192.8–915.3) 34 1041.0 (699.6–1548.9) 34 766.4 (468.4–1253.8)
Post-booster  34 1764.6 (1243.6–2503.8) 32 2640.6 (2083.3–3346.8) 33 2123.4 (1493.0–3020.1)
19F  Pre-vac. 29 4.5 (3.6–5.6) 25 4.0 (4.0–4.0) 29 4.0 (4.0–4.0)
Post-dose  2 32 794.3 (476.6–1324.0) 28 420.7 (197.4–896.4) 27 625.4 (266.5–1467.7)
Pre-booster  30 173.3 (86.1–349.0) 34 210.1 (118.4–373.0) 34 260.7 (138.0–492.5)
Post-booster  36 1248.5 (740.4–2105.3) 34 1823.7 (1252.9–2654.5) 34 1625.3 (931.7–2835.3)
23F  Pre-vac. 29 7.1 (3.7–13.7) 24 14.0 (4.8–40.5) 25 6.9 (3.1–15.1)
Post-dose  2 34 1735.5 (833.6–3613.3) 28 3621.8 (2431.4–5395.2) 29 2502.5 (1610.5–3888.6)
Pre-booster  32 989.7 (419.2–2336.8) 33 1635.9 (691.7–3868.8) 33 897.4 (381.6–2110.4)
Post-booster  35 3598.5 (2422.2–5345.9) 35 6108.0 (4335.9–8604.5) 36 5296.1 (3857.9–7270.4)
Cross-reactive serotypes
6A  Pre-vac. 23 7.5 (3.6–15.9) 25 9.1 (4.5–18.4) 28 12.6 (5.3–30.4)
Post-dose  2 31  225.3 (83.3–608.8) 21 186.2 (55.3–627.2) 27 364.5 (158.7–837.1)
Pre-booster  31 58.9 (21.6–160.3) 33 99.4 (39.9–247.8) 32 221.7 (93.8–524.0)
Post-booster  34 308.0 (141.0–672.9) 31 348.2 (154.9–782.5) 32 554.3 (248.3–1237.6)
19A  Pre-vac. 29 4.0 (4.0–4.0) 26 4.2 (3.8–4.6) 29 4.4 (3.9–5.0)
Post-dose  2 34 246.0 (109.7–551.7) 28 363.2 (202.1–652.8) 29 349.9 (177.1–691.6)
Pre-booster  33 56.7 (25.2–127.9) 35 76.4 (36.3–160.7) 32 87.8 (40.6–189.7)
34 
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cPost-booster  34 746.3 (407.8–1365.6) 
, Number of toddlers with available results; GMT, geometric mean titer; 95% CI, 95
esponse to vaccination. A different immune response in adults and
oddlers was also observed in a study that characterized circulat-
ng antigen-speciﬁc CD4+ T cells responsive to six pneumococcal
rotein antigens (including PhtD and Ply). Adults had circulating
emory CD4+ T cells that could be stimulated by all tested anti-
ens, whereas young children had a more limited response with
on-memory type antigen-speciﬁc T cells [27]. Further support
o this hypothesis comes from the trial in adults preceding the
urrent study, in which immune responses to Ply and PhtD after 2-
ose priming with PHiD-CV/dPly/PhtD (10 or 30 g formulation),
easured by the same assay, seemed to be generally higher than
eported here in toddlers [19].
There was a high level of baseline seropositivity for antibod-
es against PhtD and Ply in toddlers. This was not unexpected
s naturally-acquired antibody levels against several pneumococ-
al protein surface antigens (including PhtD) and Ply have been989.3 (652.5–1500.0) 34 725.9 (367.8–1432.6)
ﬁdence interval; OPA, opsonophagocytic activity.
reported  to increase with age (from 6–9 months to 2 years) and
exposure (nasopharyngeal carriage, acute otitis media) [28–30].
Nevertheless, we observed increases in antibody GMCs, indicating
priming and boosting effect in the toddler population.
Measuring elicited antibody levels is the most common way
of monitoring vaccine immunogenicity. However, these levels do
not always correlate well with protection [31] and a correlate of
protection for pneumococcal protein vaccines has not yet been
established. A toxin neutralization assay to measure functional
activity of antibodies against Ply has already been reported, and
antibody levels elicited by a dPly-containing vaccine were found to
correlate with neutralizing activity [26], but a standardized assay
is not available. For antibodies against PhtD, no functional assays
have yet been described. Development of these functional assays
will be important to establish potential correlates of protection
for the protein components. Moreover, further assessment of the
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iological impact of pneumococcal protein-containing vaccines
n clinical studies evaluating impact on pneumococcal carriage or
fﬁcacy against disease endpoints will be valuable to assess their
linical value. However, it is not yet clear which endpoints are
dequate for licensure of these new vaccines [32].
Another limitation of the current study is the lower number of
nrolled toddlers than planned (51 or 52 per group, instead of 60),
ecause of increasing difﬁculty to ﬁnd eligible children due to inclu-
ion of the PCV vaccines in the Czech universal mass vaccination
rogram, and a lower acceptance of vaccines by the parents after
he H1N1 pandemic and due to anti-vaccination movements. This
ower number of participants could have limited the probability
f detecting a potential signiﬁcant difference in the incidence of
rade 3 fever. Nevertheless, the upper limits of the group difference
Is were below 10% and the primary objective was  thus reached,
espite the lower power of the study.
To conclude, this study showed that the investigational vac-
ines containing pneumococcal dPly and PhtD proteins were
ell-tolerated and immunogenic in toddlers. These results support
urther development of the investigational vaccines, including their
valuation in infants.
Synﬂorix  is a trademark of the GlaxoSmithKline group of com-
anies.
onﬂict of interest
R.P.  declares he received payment for lectures, board member-
hip, consultancy and attending meetings from GlaxoSmithKline
roup of companies and other vaccine manufacturers, and his insti-
ution received grants from GlaxoSmithKline group of companies.
.P. declares he received payment for board membership, prepa-
ation of educational presentations and attending meetings from
laxoSmithKline group of companies and other vaccine manufac-
urers, and his institution received grants from GlaxoSmithKline
roup of companies. J.U.R. was and M.T., and D.B. are employees
f GlaxoSmithKline group of companies; J.U.R. and D.B. declare
tock/share options ownership in GlaxoSmithKline group of com-
anies.
uthors’ contributions
R.P.  and P.P. coordinated the clinical aspects of the study. R.P. and
.P. collected data. R.P., M.T., J.U.R. and D.B. planned and designed
he study and interpreted the results. M.T. did the statistical anal-
ses. All authors critically reviewed the different drafts of the
anuscript and approved the ﬁnal version.
unding
GlaxoSmithKline Biologicals SA was the funding source and was
nvolved in all stages of the study conduct and analysis. Glax-
SmithKline Biologicals SA also took responsibility for all costs
ssociated with the development and publishing of the present
anuscript.
revious publications
The  results of this study were presented in part at the 8th Inter-
ational Symposium on Pneumococci & pneumococcal Diseases,
guacu Falls, Brazil, March 11–15, 2012cknowledgments
The authors would like to thank the parents and their children
ho participated in this study; the staff members of the study
[2 (2014) 3025–3034 3033
centers  for their contributions to the study; the other investigators
involved in conducting the study (V. Nemec, L. Tyce, V. Dvorakova,
A. Kyjonkova, P. Mikyska, L. Petvaldska, M.  Panek, R. Ruzkova and J.
Vales); the staff of the GlaxoSmithKline laboratory for performing
immune testing; and clinical operation for study management.
The authors also thank L. Manciu (GlaxoSmithKline Vaccines) for
protocol development; J. Vandewalle (XPE Pharma & Science on
behalf of GlaxoSmithKline Vaccines) for drafting the manuscript;
A. Skwarek-Maruszewska and B. van Heertum (XPE Pharma &
Science on behalf of GlaxoSmithKline Vaccines) for manuscript
coordination.
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/j.vaccine.
2014.03.066.
References
[1] Lynch III JP, Zhanel GG. Streptococcus pneumoniae: epidemiology and risk fac-
tors, evolution of antimicrobial resistance, and impact of vaccines. Curr Opin
Pulm Med  2010;16(3):217–25.
[2] O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M,  McCall N, et al.
Burden of disease caused by Streptococcus pneumoniae in children younger than
5  years: global estimates. Lancet 2009;374(9693):893–902.
[3]  Grijalva CG, Nuorti JP, Arbogast PG, Martin SW,  Edwards KM,  Grifﬁn MR.
Decline in pneumonia admissions after routine childhood immunisation with
pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet
2007;369(9568):1179–86.
[4]  Crisinel PA, Chevalier I, Rallu F, Tapiero B, Lamarre V, Thibault R, et al. Invasive
pneumococcal disease after implementation of a reduced three-dose pneumo-
coccal conjugate vaccine program: a pediatric tertiary care center experience.
Eur J Pediatr 2010;169(11):1311–5.
[5] Pilishvili T, Lexau C, Farley MM,  Hadler J, Harrison LH, Bennett NM, et al. Sus-
tained reductions in invasive pneumococcal disease in the era of conjugate
vaccine. J Infect Dis 2010;201(1):32–41.
[6] Weinberger DM, Malley R, Lipsitch M.  Serotype replacement in disease after
pneumococcal vaccination. Lancet 2011;378(9807):1962–73.
[7]  Kaplan SL, Barson WJ,  Lin PL, Stovall SH, Bradley JS, Tan TQ, et al. Serotype
19A is the most common serotype causing invasive pneumococcal infections
in children. Pediatrics 2010;125(3):429–36.
[8] Beall B, McEllistrem MC,  Gertz Jr RE, Wedel S, Boxrud DJ, Gonzalez AL, et al. Pre-
and postvaccination clonal compositions of invasive pneumococcal serotypes
for isolates collected in the United States in 1999, 2001, and 2002. J Clin Micro-
biol 2006;44(3):999–1017.
[9]  Emergence of antimicrobial-resistant serotype 19A Streptococcus
pneumoniae—Massachusetts, 2001–2006. MMWR  Morb Mortal Wkly
Rep 2007;56(41):1077–80.
10]  Lee GM, Kleinman K, Pelton SI, Hanage W,  Huang SS, Lakoma M,  et al. Impact of
13-valent pneumococcal conjugate vaccination on Streptococcus pneumoniae
carriage in young children in Massachusetts. J Pediat Infect Dis Soc 2013.
11] Demczuk WH,  Martin I, Grifﬁth A, Lefebvre B, McGeer A, Shane A, et al. Serotype
distribution of invasive Streptococcus pneumoniae in Canada during the intro-
duction of the 13-valent pneumococcal conjugate vaccine, 2010–2012. Can J
Microbiol 2012;58(8):1008–17.
12] Kaplan SL, Barson WJ,  Lin PL, Romero JR, Bradley JS, Tan TQ, et al. Early trends for
invasive pneumococcal infections in children after the introduction of the 13-
valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2013;32(3):203–7.
13] Pichichero ME,  Kaur R, Casey JR, Xu Q, Almudevar A, Ochs M.  Antibody response
to Streptococcus pneumoniae proteins PhtD, LytB, PcpA, PhtE and Ply after
nasopharyngeal colonization and acute otitis media in children. Hum Vaccin
Immunother 2012;8(6):799–805.
14] Alexander JE, Lock RA, Peeters CC, Poolman JT, Andrew PW,  Mitchell TJ, et al.
Immunization of mice with pneumolysin toxoid confers a signiﬁcant degree of
protection against at least nine serotypes of Streptococcus pneumoniae. Infect
Immun  1994;62(12):5683–8.
15] Ogunniyi AD, Woodrow MC,  Poolman JT, Paton JC. Protection against Strep-
tococcus pneumoniae elicited by immunization with pneumolysin and CbpA.
Infect Immun 2001;69(10):5997–6003.
16] Garcia-Suarez MM,  Cima-Cabal MD,  Florez N, Garcia P, Cernuda-Cernuda R,
Astudillo A, et al. Protection against pneumococcal pneumonia in mice by
monoclonal antibodies to pneumolysin. Infect Immun 2004;72(8):4534–40.
17] Godfroid F, Hermand P, Verlant V, Denoel P, Poolman JT. Preclinical evalua-
tion of the Pht proteins as potential cross-protective pneumococcal vaccine
antigens. Infect Immun 2011;79(1):238–45.
18] Denoel P, Philipp MT,  Doyle L, Martin D, Carletti G, Poolman JT. A
protein-based pneumococcal vaccine protects rhesus macaques from pneu-
monia after experimental infection with Streptococcus pneumoniae. Vaccine
2011;29(33):5495–501.
3 cine 3
[
[
[
[
[
[
[
[
[
[
[
[
[
Haemophilus inﬂuenzae: a randomised double-blind efﬁcacy study. Lancet
2006;367(9512):740–8.034 R. Prymula et al. / Vac
19] Leroux-Roels G, Maes C, De Boever F, Traskine M,  Rüggeberg JU, Borys D.
Safety/reactogenicity results of a phase I clinical trial of an investigational
pneumococcal protein-based vaccine in adults. 8th ISPPD meeting; 2012.
20]  Prymula R, Schuerman L. 10-valent pneumococcal nontypeable Haemophilus
inﬂuenzae PD conjugate vaccine: Synﬂorix. Expert Rev Vaccines
2009;8(11):1479–500.
21] Findlay JW,  Smith WC,  Lee JW,  Nordblom GD, Das I, DeSilva BS, et al. Valida-
tion of immunoassays for bioanalysis: a pharmaceutical industry perspective.
J Pharm Biomed Anal 2000;21(6):1249–73.
22] Poolman JT, Frasch CE, Kayhty H, Lestrate P, Madhi SA, Henckaerts I. Evalu-
ation of pneumococcal polysaccharide immunoassays using a 22F adsorption
step with serum samples from infants vaccinated with conjugate vaccines. Clin
Vaccine Immunol 2010;17(1):134–42.
23] Henckaerts I, Durant N, De GD, Schuerman L, Poolman J. Validation of a routine
opsonophagocytosis assay to predict invasive pneumococcal disease efﬁcacy
of conjugate vaccine in children. Vaccine 2007;25(13):2518–27.
24]  Seiberling M,  Bologa M,  Brookes R, Ochs M,  Go K, Neveu D, et al. Safety and
immunogenicity of a pneumococcal histidine triad protein D vaccine candidate
in adults. Vaccine 2012;30(52):7455–60.
25] Bologa M,  Kamtchoua T, Hopfer R, Sheng X, Hicks B, Bixler G, et al. Safety
and immunogenicity of pneumococcal protein vaccine candidates: monova-
lent choline-binding protein A (PcpA) vaccine and bivalent PcpA-pneumococcal
histidine triad protein D vaccine. Vaccine 2012;30(52):7461–8.
26]  Kamtchoua T, Bologa M,  Hopfer R, Neveu D, Hu B, Sheng X, et al.
Safety and immunogenicity of the pneumococcal pneumolysin derivative
PlyD1 in a single-antigen protein vaccine candidate in adults. Vaccine
2013;31(2):327–33.
[2 (2014) 3025–3034
27] Sharma SK, Roumanes D, Almudevar A, Mosmann TR, Pichichero ME.  CD4 T-
cell responses among adults and young children in response to Streptococcus
pneumoniae and Haemophilus inﬂuenzae vaccine candidate protein antigens.
Vaccine 2013;31(30):3090–7.
28] Rapola S, Jantti V, Haikala R, Syrjanen R, Carlone GM, Sampson JS, et al. Natural
development of antibodies to pneumococcal surface protein A, pneumococcal
surface adhesin A, and pneumolysin in relation to pneumococcal carriage and
acute otitis media. J Infect Dis 2000;182(4):1146–52.
29]  Holmlund E, Quiambao B, Ollgren J, Jaakkola T, Neyt C, Poolman J, et al. Antibod-
ies to pneumococcal proteins PhtD, CbpA, and LytC in Filipino pregnant women
and their infants in relation to pneumococcal carriage. Clin Vaccine Immunol
2009;16(6):916–23.
30]  Holmlund E, Quiambao B, Ollgren J, Nohynek H, Kayhty H. Development
of natural antibodies to pneumococcal surface protein A, pneumococ-
cal surface adhesin A and pneumolysin in Filipino pregnant women  and
their infants in relation to pneumococcal carriage. Vaccine 2006;24(1):
57–65.
31] Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, et al. Pneu-
mococcal capsular polysaccharides conjugated to protein D for prevention of
acute otitis media caused by both Streptococcus pneumoniae and non-typable32]  Ginsburg AS, Nahm MH,  Khambaty FM,  Alderson MR.  Issues and challenges
in the development of pneumococcal protein vaccines. Expert Rev Vaccines
2012;11(3):279–85.
